期刊
CANCER CELL
卷 30, 期 3, 页码 404-417出版社
CELL PRESS
DOI: 10.1016/j.ccell.2016.08.006
关键词
-
资金
- NCI NIH HHS [R01 CA184922] Funding Source: Medline
- NHLBI NIH HHS [R01 HL082945] Funding Source: Medline
- NIDDK NIH HHS [R01 DK087992, R24 DK099808, R24 DK094746] Funding Source: Medline
More than 80% of patients with the refractory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) have mutations in Splicing Factor 3B, Subunit 1 (SF3B1). We generated a conditional knockin mouse model of the most common SF3B1 mutation, Sf3b1(K700E). sf3b1(K700E) mice develop macrocytic anemia due to a terminal erythroid maturation defect, erythroid dysplasia, and long-term hematopoietic stem cell (LT-HSC) expansion. Sf3b1(K700E) myeloid progenitors and SF3B1-mutant MDS patient samples demonstrate aberrant 3' splice-site selection associated with increased nonsense-mediated decay. Tet2 loss cooperates with Sf3b1(K700E) to cause a more severe erythroid and LT-HSC phenotype. Furthermore, the spliceosome modulator, E7017, selectively kills Sf3B1(K700E)-expressing cells. Thus, Sf3B1(K700E) expression reflects the phenotype of the mutation in MDS and may be a therapeutic target in MDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据